Back

Learner’s Digest International (TM)

  • Immunotherapy, Adoptive
  • Multiple Myeloma

CAR T-Cells and Bispecifics in Myeloma

The goal of this program is to improve management of multiple myeloma (MM) with immunotherapy. After hearing and assimilating this program, the clinicians will be able to:Compare the toxicities associated with currently approved therapies to manage MM.Appraise the latest evidence-based data regarding available therapies for treatment of MM.Maximize MM treatment outcomes through proper sequencing and combination of therapies.

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.

Credit types

AMA PRA Category 1 Credit™Up to 1.5 credits

MOC types

ABIM — Medical KnowledgeUp to 1.5 points

FDA REMS

No

Qualifies for MIPS

No

Pricing

Membership pricing — $1,095 / year

This provider prices CME through membership. Individual courses may also be sold separately.

See plans on audio-digest.org

Listed by the provider

  • Enduring / On-demand
  • Credit · Up to 1.5 credits
  • MOC · Up to 1.5 points
  • Membership pricing
  • Released
    Sep 1, 2026
  • Last day to claim credit
    Jun 8, 2027 8 months left